In Q4 2025, Prestige Consumer Healthcare Inc (PBH) reported a robust revenue of $296.8 million, reflecting a year-over-year increase of 7.1% despite economic uncertainties. This performance was underscored by a sustained demand for key products in both the North American and International segments, particularly within gastrointestinal (GI) health and women's health categories. The strategic pivot to enhance brand investments and e-commerce capabilities has further solidified PBH's market position, enabling it to navigate challenges such as supply chain disruptions and an inflationary environment effectively.
Management reported a noteworthy adjusted diluted EPS of $1.32, a substantial increase from the $1.02 recorded in Q4 2024. This advancement is attributed to improved gross margins, lower interest expenses, and disciplined cost management. The strategic approach to targeted marketing and innovation should continue to drive revenue and profitability in fiscal 2026, as affimed by management’s guidance of expected revenues between $1.14 billion and $1.155 billion.